

CITATION REPORT

List of articles citing

CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease

DOI: 10.1080/14712598.2019.1653848

Expert Opinion on Biological Therapy, 2019, 19, 971-978.

Source: <https://exaly.com/paper-pdf/71890153/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|---|--|------|-----------|
| 6 | A Challenging Colectomy for Acute Severe Ulcerative Colitis Complicated by COVID-19. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, e120-e122 | 4.5 | 4 |
| 5 | Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic.. <i>Frontline Gastroenterology</i> , 2022 , 13, 89-90 | 2.6 | 4 |
| 4 | The global landscape on interchangeability of biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-16 | 5.4 | 2 |
| 3 | Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2021 , 160, 2340-2353 | 13.3 | 17 |
| 2 | Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>BioDrugs</i> , 2021 , 35, 715-733 | 7.9 | 4 |
| 1 | Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study. 2022 , 10, 2130 | | 0 |